SEC ownership of Compass Therapeutics, Inc.

Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001738021.

Comparable stake leader

TANG CAPITAL MANAGEMENT LLC

Disclosed value leader

TANG CAPITAL MANAGEMENT LLC

Comparable rows

50/50

Latest evidence

31 Mar 2026

Top shareholders Insider holders Latest transactions
Public ticker
CMPX on Nasdaq
Parsed ownership sources
13F and 13D/G
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
Largest SEC-reported holder
TANG CAPITAL MANAGEMENT LLC
Ranking: Comparable ownership first, then disclosed value
Ownership snapshot CIK-linked ownership evidence from parsed SEC filings. 3 signals
Comparable ownership rows
50 of 50
Meaning: Rows with safely comparable ownership %
Latest 13D/G holder
TANG CAPITAL MANAGEMENT LLC
Source: Latest parsed Schedule 13D/G stake
Latest parsed ownership date
31 Mar 2026
Freshness: Most recent filing date in this holder set
Issuer Names, identifiers, and filing context for this profile. 2 identity fields
Issuer CIK
0001738021
Issuer location
Boston, MA

Ownership snapshot

Top shareholders of Compass Therapeutics, Inc. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
TANG CAPITAL MANAGEMENT LLC
Disclosed value leader
TANG CAPITAL MANAGEMENT LLC
Comparable rows
50/50
Latest evidence
31 Mar 2026
13F 13D/G Lead comparable stake: 10% 13D/G row: TANG CAPITAL MANAGEMENT LLC Showing 1-8 of 50 holder rows.

Quick read

TANG CAPITAL MANAGEMENT LLC leads the comparable SEC ownership view at 10%.

50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens TANG CAPITAL MANAGEMENT LLC's linked filing trail.
Comparable ownership Top 5
TANG CAPITAL MANAGEMENT LLC 10%
ORBIMED ADVISORS LLC 8.9%
SUVRETTA CAPITAL MANAGEMENT, LLC 8.2%
STATE STREET CORP 5.5%
BlackRock, Inc. 5.2%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-8 of 50 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
TANG CAPITAL MANAGEMENT LLC
13F 13D/G
Company
13F 13D/G
10%
from 13D/G
$88,823,380
16,790,809 shares
 — 31 Mar 2026
ORBIMED ADVISORS LLC
13F 13D/G
Company
13F 13D/G
8.9%
from 13D/G
$80,513,768
15,219,994 shares
 — 31 Mar 2026
SUVRETTA CAPITAL MANAGEMENT, LLC
13F 13D/G
Company
13F 13D/G
8.2%
from 13D/G
$75,686,035
14,307,379 shares
 — 31 Mar 2026
STATE STREET CORP
13F 13D/G
Company · STATE STREET CORPORATION
13F 13D/G
5.5%
from 13D/G
$35,416,423
6,694,976 shares
 — 31 Mar 2026
BlackRock, Inc.
13F 13D/G
Company
13F 13D/G
5.2%
from 13D/G
$50,287,163
9,506,080 shares
 — 31 Mar 2026
Vivo Opportunity Fund Holdings, L.P.
13D/G
13D/G
5.1%
$31,485,926
8,995,979 shares
 $0 30 Sep 2025
Commander Aggregator, LP
13D/G
13D/G
4.5%
$24,610,554
7,788,150 shares
 $0 14 Aug 2025
ADAGE CAPITAL PARTNERS GP, L.L.C.
13F 13D/G
Company · Adage Capital Management, L.P.
13F 13D/G
4.4%
from 13D/G
$44,893,585
8,486,500 shares
 — 31 Mar 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Forms 3/4/5 flow

Insider trading overview

Net insider flow leans to buying over the last 12 months. Net value: +$75,600.

Buys
$75,600
Insiders: 2
Sells
$0
Insiders: 0
Net
+$75,600
Shares: +40,000
Window
Last 12 months
4 rolling buckets
Buy value Sell value
Shares: 40,000 Shares: 0
Window (months) Buy shares Sell shares Buy value Sell value Net value
0-3 0 0 $0 $0 $0
3-6 40,000 0 $75,600 $0 +$75,600
6-9 0 0 $0 $0 $0
9-12 0 0 $0 $0 $0

Reporting owners

Insider holders from Forms 3/4/5

Showing 1-19 of 19 reporting-owner rows connected to Compass Therapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.

Rows
19
Largest Forms 3/4/5 holder
Thomas J. Schuetz
Net 12M change
+$75,600
Latest report
29 Apr 2026
Name Relationship Holdings Value Past Year Net Change Change % Valuation Report Date
Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director $43,053,750 Mixed 08 Feb 2026
Vered Bisker-Leib CHIEF EXECUTIVE OFFICER, Director $4,530,418 Mixed 08 Feb 2024
Barry Shin Cfo $2,714,250 Mixed 02 Jan 2026
Neil Lerner Chief Accounting Officer $751,275 +$28,350 +3.9% Filing P/S 29 Apr 2026
Jonathan Anderman General Counsel $370,440 +$47,250 +15% Filing P/S 29 Apr 2026
ORBIMED ADVISORS LLC Director, 10%+ Owner $0 Mixed 09 Apr 2025
Carl L. Gordon Director $0 Mixed 02 Jan 2026
Susan Kalled Chief Scientific Officer Mixed 18 Feb 2022
Philip Ferneau Director Mixed 02 Jan 2026
Brett Kaplan Director Mixed 18 Feb 2022
David M. Wurzer Director Mixed 08 Feb 2023
Stephen P. Squinto Director Mixed 18 Feb 2022
James P. Boylan Director Mixed 02 Jan 2026
Ellen Chiniara Director Mixed 02 Jan 2026
Miranda Jayne Toledano Director Mixed 25 Jun 2021
Arjun Prasad Chief Commercial Officer Mixed 02 Jan 2026
Cynthia Sirard Chief Medical Officer Mixed 02 Jan 2026
Mary Ann Gray Director Mixed 02 Jan 2026
Richard S. Lindahl Director Mixed 02 Jan 2026

Recent insider transactions for Compass Therapeutics, Inc.

Showing up to 300 recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % SEC-reported value SEC-reported price Shares Shares owned Date Ownership
Neil Lerner CMPX Common Stock Purchase 3.92% $28,350 $1.89 15,000 397,500 29 Apr 2026 Direct
Jonathan Anderman CMPX Common Stock Purchase 14.6% $47,250 $1.89 25,000 196,000 29 Apr 2026 Direct
Thomas J. Schuetz CMPX Common Stock Tax liability -0.55% -36,687 6,603,336 08 Feb 2026 Direct
Thomas J. Schuetz CMPX Common Stock Tax liability -0.7% -46,777 6,640,023 09 Jan 2026 Direct
Barry Shin CMPX Common Stock Award 31.2% 125,000 525,000 02 Jan 2026 Direct
Barry Shin CMPX Stock Option (Right to Buy) Award 670,000 670,000 02 Jan 2026 Direct
Cynthia Sirard CMPX STOCK OPTION (RIGHT TO BUY) Award 1,000,000 1,000,000 02 Jan 2026 Direct
Thomas J. Schuetz CMPX Common Stock Award 3.88% 250,000 6,686,800 02 Jan 2026 Direct
Thomas J. Schuetz CMPX Stock Option (Right to Buy) Award 2,000,000 2,000,000 02 Jan 2026 Direct
Arjun Prasad CMPX STOCK OPTION (RIGHT TO BUY) Award 1,000,000 1,000,000 02 Jan 2026 Direct
Richard S. Lindahl CMPX Stock Option (Right to Buy) Award 90,000 90,000 02 Jan 2026 Direct
Ellen Chiniara CMPX Stock Option (Right to Buy) Award 90,000 90,000 02 Jan 2026 Direct
Neil Lerner CMPX Common Stock Award 19.5% 62,500 382,500 02 Jan 2026 Direct
Neil Lerner CMPX Stock Option (Right to Buy) Award 435,000 435,000 02 Jan 2026 Direct
Mary Ann Gray CMPX Stock Option (Right to Buy) Award 90,000 90,000 02 Jan 2026 Direct
James P. Boylan CMPX Stock Option (Right to Buy) Award 90,000 90,000 02 Jan 2026 Direct
Carl L. Gordon CMPX Stock Option (Right to Buy) Award 90,000 90,000 02 Jan 2026 Direct
Philip Ferneau CMPX Stock Option (Right to Buy) Award 90,000 90,000 02 Jan 2026 Direct
Jonathan Anderman CMPX Common Stock Award 714.3% 150,000 171,000 02 Jan 2026 Direct
Jonathan Anderman CMPX Stock Option (Right to Buy) Award 720,000 720,000 02 Jan 2026 Direct
Thomas J. Schuetz CMPX Common Stock Tax liability -0.68% -44,025 6,436,800 16 Nov 2025 Direct
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .